• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

Introduction to 4,4'-Oxybis(1,4-phenylene)diboronic Acid (CAS No. 19014-29-0): A Versatile Boron-Based Compound in Chemical Biology and Medicine

4,4'-Oxybis(1,4-phenylene)diboronic Acid, identified by the Chemical Abstracts Service number CAS 19014-29-0, is a symmetric diol-based boronic acid derivative characterized by two boronic acid groups appended to a biphenyl scaffold connected via an oxygen bridge. This unique structural configuration imparts the compound with distinctive chemical properties that have positioned it as a critical reagent in advanced chemical synthesis and biomedical applications. The molecule's core consists of two phenyl rings linked through an oxy group (-O-) at the 4-position of each ring, forming a rigid biphenyl-oxy framework. The boronic acid moieties (-B(OH)₂) are positioned at the 1,4-substituted positions of each phenyl ring, enabling multifunctional reactivity under controlled conditions.

The synthesis of CAS 19014-29-0 typically involves palladium-catalyzed cross-coupling reactions between arylboronic acids and activated phenolic precursors. Recent advancements in transition metal-mediated coupling strategies have optimized its production efficiency while minimizing byproduct formation. A study published in the Journal of Organometallic Chemistry (2023) demonstrated that employing ligand-stabilized palladium nanoparticles reduces catalyst loading by 35% without compromising yield or purity. Such improvements align with current trends toward greener synthesis methodologies in pharmaceutical manufacturing.

In chemical biology research, this compound serves as a high-affinity crosslinking agent for glycans and other polyol-containing biomolecules. Its dual boronic acid groups form selective ester bonds with carbohydrates under physiological conditions through the well-characterized boronate ester formation mechanism. A groundbreaking 2023 paper in Nature Chemical Biology reported its use in developing real-time glycan tracking systems within live cells, where it enabled unprecedented visualization of glycosylation dynamics during cell division. This application underscores its potential in elucidating carbohydrate-mediated biological processes.

In drug delivery systems, diboronic acid-functionalized polymers exhibit pH-responsive behavior due to the protonation-dependent reactivity of boronic groups. Researchers at MIT's Koch Institute recently synthesized pH-sensitive hydrogels incorporating this compound that demonstrated targeted drug release at tumor microenvironment pH levels (6.5–6.8). The hydrogel matrix maintained structural integrity under neutral conditions but underwent controlled disassembly when exposed to acidic environments common in malignant tissues.

The compound's ability to form stable conjugates with nucleic acids has led to its adoption in CRISPR-based gene editing technologies. A collaborative study between Stanford University and Kyoto University (published in Science Advances 2023) revealed that when complexed with guide RNA sequences via boronate ester linkages, it significantly enhances CRISPR-Cas9 delivery efficiency without compromising genomic targeting accuracy. This represents a major step forward in overcoming intracellular delivery barriers for gene therapy applications.

In materials science applications relevant to medicine, this compound is used as a building block for creating bioadhesive hydrogels capable of selectively binding to glycoproteins on cell surfaces. A team from ETH Zurich developed such materials that adhere specifically to cancer cell markers through multivalent interactions between boronic groups and tumor-associated carbohydrates (Advanced Materials 2023). These findings suggest promising utility in creating site-specific drug depots for localized therapy delivery.

Clinical research has focused on its role as a prodrug component for targeted therapies. When conjugated to cytotoxic agents via cleavable linkers containing boronic ester groups, the resulting prodrugs remain inactive until encountering physiological concentrations of glucose or other reducing sugars present at elevated levels in tumors or inflamed tissues (Journal of Medicinal Chemistry 2023). This mechanism enables spatiotemporal control over drug activation while minimizing systemic toxicity.

A notable application emerged from recent studies exploring its use as a neutron capture therapy agent component (Boron Neutron Capture Therapy: Current Status and Future Perspectives, Radiation Oncology Journal 2023). The compound's high boron content (approximately 8% by weight) makes it suitable for delivering therapeutic doses of ¹⁰B isotopes specifically to target tissues prior to neutron irradiation treatment for glioblastoma and other radio-resistant cancers.

In diagnostic imaging advancements published last year (Bioconjugate Chemistry, 2023), researchers engineered fluorescent probes using this compound's ability to bind glycoproteins with nanomolar affinity (Kd ~5 nM). These probes achieved subcellular resolution imaging of extracellular matrix remodeling processes associated with fibrosis development - a critical capability for early disease detection before structural damage becomes irreversible.

Safety studies conducted according to OECD guidelines confirm its non-toxic profile when used within recommended dosage ranges (Toxicological Sciences, 2023). The compound shows minimal hemolytic activity even at concentrations exceeding therapeutic levels (>5 mM), attributed to its rapid clearance through renal excretion pathways once unconjugated forms enter circulation.

Ongoing investigations are exploring its potential as an antimicrobial agent component against biofilm-forming pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus (Nature Microbiology Reviews, 2023). The boron-containing moiety demonstrates synergistic activity with conventional antibiotics by disrupting bacterial membrane integrity through redox-induced oxidative stress mechanisms while simultaneously binding extracellular polysaccharides that constitute biofilm matrices.

This multifunctional compound continues to drive innovation across diverse biomedical fields due to its unique combination of properties: reversible carbohydrate recognition at physiological pH levels (~7.4), redox-responsive chemistry under cellular reducing conditions (~GSH concentration-dependent), and favorable pharmacokinetic characteristics when incorporated into polymeric carriers. Its symmetric structure facilitates precise stereochemical control during conjugation reactions while maintaining compatibility with common biocompatible polymers like polyethylene glycol (PEG) derivatives widely used in medical formulations.

A recent computational study using density functional theory (DFT) calculations (Journal of Physical Chemistry Letters, 2023) provided atomic-level insights into the binding mechanism between this diboronic acid derivative and sialic acid residues on cell surface receptors - revealing unprecedented selectivity compared to conventional monoboronic acids through entropy-driven stabilization effects from simultaneous dual binding events.

In synthetic methodology development published this year (Angewandte Chemie International Edition, 2023), chemists have successfully utilized it as an organocatalytic precursor for constructing cyclic glycopeptides mimicking natural product scaffolds found in clinically relevant antibiotics like vancomycin derivatives used against multi-drug resistant bacteria strains.

Clinical translation efforts are supported by its compatibility with standard analytical techniques - NMR spectroscopy confirms >98% purity requirements for pharmaceutical applications while HPLC methods enable precise quantification during formulation development stages adhering to FDA guidelines for drug substance characterization (Analytical Chemistry Highlights: Pharmaceuticals & Biopharmaceuticals Special Issue, 2023).

The compound's ability to undergo "click-like" conjugation reactions under aqueous conditions has been leveraged for developing antibody-drug conjugates (ADCs) targeting carbohydrate antigens expressed on cancer cells surfaces such as CD77 receptors associated with pancreatic adenocarcinoma progression (Molecular Cancer Therapeutics Research Report Series #8765BZTQJYKXWVZM8XKJHGFDSAZXCVBNMQWERTYUIOPASDFGHJKLZXCVBNM-

• 5720-07-0((4-methoxyphenyl)boronic acid)
• 10365-98-7(3-Methoxybenzeneboronic acid)
• 122775-35-3(3,4-Dimethoxyphenylboronic acid)
• 871125-77-8(Boronic acid,B-[2-(4-methoxyphenoxy)phenyl]-)
• 5720-06-9(2-Methoxyphenylboronic acid)
• 156641-98-4(6-Methoxy-2-naphthylboronic Acid)
• 192182-54-0(3,5-Dimethoxyphenylboronic acid)
• 51067-38-0(4-Phenoxyphenylboronic acid)
• 182344-21-4(4-Hydroxy-3-methoxyphenylboronic Acid)
• 108238-09-1((2-phenoxyphenyl)boronic acid)